Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study
Journal of Clinical Medicine · 14.07.2026 · 15 (14) · 5507
DOI: 10.3390/jcm15145507 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 14.07.2026. Verfasst von Chiaki Maeyashiki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japanese Ministry of Health, Labour and Welfare.
Abstract (Originalsprache)
Background/Objectives: Upadacitinib is recommended for moderate-to-severe ulcerative colitis (UC); however, data regarding its effectiveness and long-term outcomes in large patient populations remain limited. In this nationwide, hospital-based cohort study, we investigated the effectiveness and long-term outcomes of upadacitinib in patients with UC.
Methods
This study included 2694 patients with UC who received upadacitinib. The primary outcome was the comparison of hospitalization rates during the 1-year periods before and after the initiation of upadacitinib. Additionally, the cumulative hospitalization rate up to 2 years post-initiation was evaluated.
Results
Of 2694 patients who were initiated on upadacitinib, the median age was 45 (31–57) years, and 60.5% were male. In the year preceding upadacitinib initiation, 29.3% of the patients were hospitalized due to UC. In the 1 year following upadacitinib initiation, the hospitalization rate significantly decreased to 9.6% (p < 0.001). Furthermore, the cumulative hospitalization rate up to 2 years was 12.6%. Among patients with a prior history of hospitalization, the hospitalization rate in the 1 year after upadacitinib initiation decreased from 100% to 16.8%. A significant improvement in the hospitalization rate was observed in both advanced therapy-naïve and -exposed patients. After adjusting for age, sex, steroid use, and history of advanced therapy, the hazard ratio (95% confidence interval) for hospitalization associated with upadacitinib initiation was 0.39 (0.33–0.46, p < 0.001).
Conclusions
The initiation of upadacitinib was associated with significantly lower hospitalization rates, and this association was maintained for up to two years. These findings support upadacitinib as an effective and viable treatment option for patients with moderate-to-severe UC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo 180-8610, Japan.
ORCID-Profile: Chiaki Maeyashiki, Yutaka Yasui, Masayuki Kurosaki
Förderung
- Japan Agency for Medical Research and Development
- Japanese Ministry of Health, Labour and Welfare
Zitieren
APA
Maeyashiki, C., Tamaki, N., Tanaka, Y., Yasui, Y., Tsuchiya, K., Nakanishi, H., & Kurosaki, M. (2026). Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study. Journal of Clinical Medicine, 15(14), 5507. https://doi.org/10.3390/jcm15145507
Vancouver
Maeyashiki C, Tamaki N, Tanaka Y, Yasui Y, Tsuchiya K, Nakanishi H, et al. Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study. Journal of Clinical Medicine. 2026;15(14):5507. doi:10.3390/jcm15145507
BibTeX
@article{Maeyashiki2026,
author = {Maeyashiki, Chiaki and Tamaki, Nobuharu and Tanaka, Yuki and Yasui, Yutaka and Tsuchiya, Kaoru and Nakanishi, Hiroyuki and Kurosaki, Masayuki},
title = {Upadacitinib Reduces Rates of Hospitalization in Ulcerative Colitis: A Large-Scale Nationwide Cohort Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {14},
pages = {5507},
doi = {10.3390/jcm15145507}
}
EUVIMED